<DOC>
	<DOCNO>NCT01428973</DOCNO>
	<brief_summary>The present project multicenter phase II trail aim compare two postgrafting immunosuppressive regimen propose study best suit prevent graft-versus-host disease ( GVDH ) . The immunosuppressive regimen consist : Tacrolimus plus Mycophenolate Mofetil Tacrolimus plus Sirolimus . Before graft patient undergo reduced-intensity conditioning Fludarabine/total body irradiation ( TBI ) Fludarabine/Busulfan/anti-thymoglobuline . Following interim analysis October 2014 , protocol amend allow inclusion Flu-TBI conditioning . The hypothesis Tacrolimus plus Sirolimus regimen associate well progression-free survival due low incidence relapse/progression .</brief_summary>
	<brief_title>Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Hematological malignancy confirm histologically rapidly progress : Acute myeloid leukemia ( AML ) complete remission ( CR ) ( define ≤ 5 % marrow blast absence blast peripheral blood ) ; Myelodysplastic syndrome ( MDS ) ≤ 5 % marrow blast absence blast peripheral blood ; Chronic myeloid leukemia ( CML ) chronic phase ( CP ) ; Myeloproliferative neoplasm blast crisis extensive marrow fibrosis ; Acute lymphoid leukemia ( ALL ) CR ; Multiple myeloma rapidly progress ; chronic lymphocytic leukemia ( CLL ) ; NonHodgkin 's lymphoma ( aggressive NHL chemosensitive disease ) ; Hodgkin 's disease chemosensitive disease ; 2 . 10/10 HLAA , B , C , DRB1 DQBI allelematched donor fit to/willing donate PBSC . 3 . Clinical situation : 1 . Theoretical indication standard allotransplant , feasible : Age &gt; 50 yr ; Unacceptable end organ performance ; At physician 's decision ; Patient 's refusal . 2 . Indication standard autotransplant : perform miniallotransplantation 26 month standard autotransplant . 4 . Other inclusion criterion : Male female ; fertile patient must use reliable contraception method ; Age ≤ 75 yr ( child age allow protocol ) ; Informed consent give patient his/her guardian minor age . Any condition fulfil inclusion criterion ; HIV positive ; Nonhematological malignancy ( y ) ( except nonmelanoma skin cancer ) &lt; 3 year nonmyeloablative hematopoietic cell transplantation ( HCT ) ; Life expectancy severely limited disease malignancy ; Administration cytotoxic agent ( ) `` cytoreduction '' within three week prior initiate nonmyeloablative transplant conditioning ( Exceptions hydroxyurea imatinib mesylate ) ; CNS involvement disease refractory intrathecal chemotherapy ; Terminal organ failure , except renal failure ( dialysis acceptable ) 1 . Cardiac : Symptomatic coronary artery disease cardiac failure require therapy ; ejection fraction &lt; 35 % ; uncontrolled arrhythmia , uncontrolled hypertension ; 2 . Pulmonary : DLCO &lt; 35 % and/or receive supplementary continuous oxygen ; 3 . Hepatic : Fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease ; Uncontrolled infection ; Karnofsky Performance Score &lt; 70 % ; Patient fertile man woman unwilling use contraceptive technique 12 month follow treatment ; Patient female pregnant breastfeeding ; Any condition precluding use sirolimus MMF ; One HLA mismatch peripheral blood stem cell ( PBSC ) fit to/willing donate .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Allogeneic hematopoeitic cell transplantation</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Reduced-intensity conditioning</keyword>
	<keyword>Immunosuppressive regimen</keyword>
	<keyword>HLA-matched donor</keyword>
	<keyword>Progression free survival</keyword>
	<keyword>Overall survival</keyword>
</DOC>